A Study of IBI362 9 mg in Chinese Adults With Obesity
Status:
Recruiting
Trial end date:
2025-09-19
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study
evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be
randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered
once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a
60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after
the end of treatment.